Suppression of progesterone by influenza A virus mediates adverse maternal and fetal outcomes in mice
Influenza A virus infection during pregnancy can cause adverse maternal and fetal outcomes but the mechanism responsible remains elusive. Infection of outbred mice with 2009 H1N1 at embryonic day (E) 10 resulted in significant maternal morbidity, placental tissue damage and inflammation, fetal growth restriction, and developmental delays that lasted through weaning. Restriction of pulmonary virus replication was not inhibited during pregnancy, but infected dams had suppressed circulating and placental progesterone (P4) concentrations that were caused by H1N1-induced upregulation of pulmonary cyclooxygenase (COX)-1-, but not COX-2-, dependent synthesis and secretion of prostaglandin (PG) F2α. Treatment with 17-α-hydroxyprogesterone caproate (17-OHPC), a synthetic progestin that is safe to use in pregnancy, ameliorated the adverse maternal and fetal outcomes from H1N1 infection and prevented placental cell death and inflammation. These findings highlight the therapeutic potential of progestin treatments for influenza during pregnancy.IMPORTANCEPregnant individuals are at risk of severe outcomes from both seasonal and pandemic influenza A viruses. Influenza infection during pregnancy is associated with adverse fetal outcomes at birth and adverse consequences for offspring into adulthood. When outbred dams, with semi-allogenic fetuses, were infected with 2009 H1N1, in addition to pulmonary virus replication, lung damage, and inflammation, the placenta showed evidence of transient cell death and inflammation that was mediated by increased activity along the arachidonic acid pathway leading to suppression of circulating progesterone. Placental damage and suppressed progesterone were associated with detrimental effects on perinatal growth and developmental delays in offspring. Treatment of H1N1-infected pregnant mice with 17-OHPC, a synthetic progestin treatment that is safe to use in pregnancy, prevented placental damage and inflammation and adverse fetal outcomes. This novel therapeutic option for the treatment of influenza during pregnancy should be explored clinically.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
mBio - 15(2024), 2 vom: 14. Feb., Seite e0306523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Creisher, Patrick S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4G7DS2Q64Y |
|---|
| Anmerkungen: |
Date Completed 15.02.2024 Date Revised 16.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2023 Nov 12;:. - PMID 37745453 Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.03065-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366807498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366807498 | ||
| 003 | DE-627 | ||
| 005 | 20240216232722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.03065-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM366807498 | ||
| 035 | |a (NLM)38190129 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Creisher, Patrick S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Suppression of progesterone by influenza A virus mediates adverse maternal and fetal outcomes in mice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2024 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Nov 12;:. - PMID 37745453 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Influenza A virus infection during pregnancy can cause adverse maternal and fetal outcomes but the mechanism responsible remains elusive. Infection of outbred mice with 2009 H1N1 at embryonic day (E) 10 resulted in significant maternal morbidity, placental tissue damage and inflammation, fetal growth restriction, and developmental delays that lasted through weaning. Restriction of pulmonary virus replication was not inhibited during pregnancy, but infected dams had suppressed circulating and placental progesterone (P4) concentrations that were caused by H1N1-induced upregulation of pulmonary cyclooxygenase (COX)-1-, but not COX-2-, dependent synthesis and secretion of prostaglandin (PG) F2α. Treatment with 17-α-hydroxyprogesterone caproate (17-OHPC), a synthetic progestin that is safe to use in pregnancy, ameliorated the adverse maternal and fetal outcomes from H1N1 infection and prevented placental cell death and inflammation. These findings highlight the therapeutic potential of progestin treatments for influenza during pregnancy.IMPORTANCEPregnant individuals are at risk of severe outcomes from both seasonal and pandemic influenza A viruses. Influenza infection during pregnancy is associated with adverse fetal outcomes at birth and adverse consequences for offspring into adulthood. When outbred dams, with semi-allogenic fetuses, were infected with 2009 H1N1, in addition to pulmonary virus replication, lung damage, and inflammation, the placenta showed evidence of transient cell death and inflammation that was mediated by increased activity along the arachidonic acid pathway leading to suppression of circulating progesterone. Placental damage and suppressed progesterone were associated with detrimental effects on perinatal growth and developmental delays in offspring. Treatment of H1N1-infected pregnant mice with 17-OHPC, a synthetic progestin treatment that is safe to use in pregnancy, prevented placental damage and inflammation and adverse fetal outcomes. This novel therapeutic option for the treatment of influenza during pregnancy should be explored clinically | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a macrophages | |
| 650 | 4 | |a placenta | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a progestins | |
| 650 | 4 | |a prostaglandins | |
| 650 | 7 | |a Progesterone |2 NLM | |
| 650 | 7 | |a 4G7DS2Q64Y |2 NLM | |
| 700 | 1 | |a Parish, Maclaine A |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Perry, Jamie L |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Ariana D |e verfasserin |4 aut | |
| 700 | 1 | |a Sherer, Morgan L |e verfasserin |4 aut | |
| 700 | 1 | |a Burd, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Sabra L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 15(2024), 2 vom: 14. Feb., Seite e0306523 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:2 |g day:14 |g month:02 |g pages:e0306523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.03065-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 2 |b 14 |c 02 |h e0306523 | ||